

Supplementary Table 3. Median survival time of the persistence of TNFi (time of 50% discontinuation)

	Total	Adalimumab	Etanercept	Infliximab	Golimumab
Total, number of patients	5,944	2,543	1,026	876	1,499
Median [lower, upper]	709 [680, 750]	651.0 [611, 681]	836.0 [777, 895]	860.5 [764, 993]	689.0 [631, 752]
Internal medicine, number of patients	5,102	2,518	967	841	776
Median [lower, upper]	763 [716, 797]	649 [610, 680]	854 [797, 932]	871 [774, 995]	971.0 [851, 1140]
Orthopedics, number of patients	622	19	42	31	530
Median [lower, upper]	602 [541, 682]	938 [309, 1498]	590 [156, 930]	834 [265, NA]	592.5 [534, 651]
Neurosurgery, number of patients	185	1	4	3	177
Median [lower, upper]	280 [228, 457]	1 [NA, NA]	243 [1, NA]	113 [1, NA]	288.0 [229, 473]
Others, number of patients	35	5	13	1	16
Median [lower, upper]	349 [194, 643]	336 [290, NA]	227 [84, NA]	49 [NA, NA]	495.5 [99, 1038]
Non-internal medicine, number of patients	842	25	59	35	723
Median [lower, upper]	528.5 [477, 575]	819 [290, 1249]	349 [176, 741]	771 [244, NA]	531 [484, 575]

TNFi, tumor necrosis factor inhibitor.